CD47 Enhances Cell Viability and Migration Ability but Inhibits Apoptosis in Endometrial Carcinoma Cells via the PI3K/Akt/mTOR Signaling Pathway
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CD47 Enhances Cell Viability and Migration Ability but Inhibits Apoptosis in Endometrial Carcinoma Cells via the PI3K/Akt/mTOR Signaling Pathway
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-08-26
DOI
10.3389/fonc.2020.01525
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instability–High Tumors
- (2019) Janelle Sobecki-Rausch et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises
- (2018) Bing Tong et al. Future Oncology
- CD47 promotes human glioblastoma invasion through activation of PI3K/Akt pathway
- (2018) Xuejian Liu et al. ONCOLOGY RESEARCH
- Knockdown of CLDN6 inhibits cell proliferation and migration via PI3K/AKT/mTOR signaling pathway in endometrial carcinoma cell line HEC-1-B
- (2018) Xia Cao et al. OncoTargets and Therapy
- Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer
- (2018) Fabio Barra et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer
- (2018) Shenglan Gu et al. Journal of Immunology Research
- Cancer immunotherapy targeting the CD47/SIRPα axis
- (2017) Kipp Weiskopf EUROPEAN JOURNAL OF CANCER
- The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer
- (2017) Hanke L. Matlung et al. IMMUNOLOGICAL REVIEWS
- A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer
- (2017) Paola A. Betancur et al. Nature Communications
- CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis
- (2017) Ran Liu et al. Oncotarget
- Endometrial cancer: Not your grandmother's cancer
- (2016) Jessica N. McAlpine et al. CANCER
- Immunotherapy in Endometrial Cancer: In the Nick of Time
- (2016) J. M. Piulats et al. CLINICAL CANCER RESEARCH
- CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
- (2016) Kipp Weiskopf et al. JOURNAL OF CLINICAL INVESTIGATION
- Expression of immune checkpoint molecules in endometrial carcinoma
- (2015) JIA LIU et al. Experimental and Therapeutic Medicine
- Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy
- (2014) Anke Vanderstraeten et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting PI3K/Akt/mTOR Signaling in Cancer
- (2014) Camillo Porta et al. Frontiers in Oncology
- Crosstalk between colon cancer cells and macrophages via inflammatory mediators and CD47 promotes tumour cell migration
- (2013) Yuan Zhang et al. EUROPEAN JOURNAL OF CANCER
- The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer
- (2012) B. M. Slomovitz et al. CLINICAL CANCER RESEARCH
- Endometrial carcinoma: molecular alterations involved in tumor development and progression
- (2012) A Yeramian et al. ONCOGENE
- The Inhibitory Role of B7-H4 in Antitumor Immunity: Association with Cancer Progression and Survival
- (2011) Changjun He et al. Clinical & Developmental Immunology
- Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints
- (2008) D Llobet et al. JOURNAL OF CLINICAL PATHOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now